St. Jude clinical trials emphasize the innovative and collaborative research between our doctors and scientists, who work together to find cures for children.
Children who are referred for a clinical trial at St. Jude will receive leading therapies, including standard and investigational treatments, in a compassionate, supportive setting that meets the highest standards of care. We provide phase 1, phase 2 and phase 3 clinical trials in childhood cancer, hematology, infectious diseases, supportive care and healthy volunteer studies.
For Physicians
We invite referring physicians and other health care providers to subscribe to our monthly Clinical Trials Alert email. This newsletter will notify you of important research protocols at St. Jude, as well as new initiatives, research news and information at the hospital.
For Families
Taking part in clinical research is a decision that should be discussed with family members and your child's doctor. We hope you will find the information in this section helpful in making the best choices for your child.
Browse Clinical Trials
-
BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 18 to 35 years old
- Diagnosed with severe sickle cell disease
CASPERKID: Study of Exa-cel in Children with Severe Sickle Cell Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (Exagamglogene Autotemcel or Exa-cel) in Subjects with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 2–11 years old
- Diagnosed with severe sickle cell disease (SCD)
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms
Diseases Treated:
Eligibility:
- 1–22 years old
- Treatment-related or secondary MDS/AML
EDO312: Edoxaban, a new Oral Anticoagulant, for Blood Clots in Children
Phase III Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban with Standard Anticoagulant Therapy in Children with Venous Thromboembolism (VTE)
Diseases Treated:
Blood clots (venous thromboembolism)
Eligibility:
This clinical trial is open only to St. Jude patients.
- Newborn to 17 years old (must be younger than 18)
- Diagnosis of blood clot in a vein (venous thromboembolism, also called VTE)
- Requires anticoagulant therapy for at least 90 days
- Received at least 5 days of heparin therapy prior to study
FIX-GT: Factor IX Gene Therapy Study for Patients with Hemophilia B
A Factor IX Gene Therapy Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients with Hemophilia B
View TrialGENETX: Assessment for Gene Therapy Decisions
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)
Diseases Treated:
Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic DiseasesEligibility:
- Non-therapeutic clinical trial
- Interviews conducted remotely
- 18-35-year-olds with rare genetic diseases
- Parents or caregivers of patients under 21 with rare genetic diseases
- Health care workers for gene therapy patients
Go-8: Gene Therapy for Hemophilia A
Gene Therapy for Hemophilia A Using a Novel Serotype 8 Capsid Pseudotyped Adeno-Associated Viral Vector Encoding Factor VIII-V3
View TrialHAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia
Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosis of severe aplastic anemia
- No available matched donor
INSIGHT-HD: Investigating the Genetics of Hematologic Diseases
Diseases Treated:
Non-malignant blood diseases (non-therapeutic)
Eligibility:
- Receiving therapy or a consultation for a non-malignant blood disorder
- Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
LEAPS: Understanding Sickle Cell Disease Transition to Adult Care
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition
Diseases Treated:
Eligibility:
This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.
- Diagnosis of sickle cell disease (SCD)
- 16 to 20 years old
- English is primary language
LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants
A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells
Diseases Treated:
X-linked Severe Combined Immunodeficiency (SCID-X1)
Eligibility:
- Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
- Newborn to 2 years of age
- No prior therapy with allogeneic stem cell transplantation
- No HIV infection
SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 25 years old or younger
- Diagnosed with severe sickle cell disease
- Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)
-
10-CBA: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant is receiving an allogeneic hematopoietic stem cell transplant at St. Jude Children’s Research Hospital using an unlicensed cord blood unit (CBU).
- The patient has a disorder affecting the hematopoietic system that is either inherited, acquired, or a result from myeloablative treatment.
BMTFU: Protocol for Collecting Long-Term Follow-Up Data on Recipients of Hematopoietic Stem Cell Transplant
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)
CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia
Diseases Treated:
Acute Myelogenous Leukemia
Eligibility:
- 21 years old or younger
- Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
- Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant
A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
- Ages 12–21 years
- Lymphoid or myeloid-based cancer that requires a bone marrow transplant
GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products
Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer
TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
For transplant recipient:
- 21 years or younger
- Does not have a suitable sibling donor or volunteer unrelated donor
- Has a suitable single haplotype matched family member donor
- Diagnosed with high risk hematologic malignancy
- No prior allogeneic hematopoietic cell transplant
HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia
Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosis of severe aplastic anemia
- No available matched donor
LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants
A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells
Diseases Treated:
X-linked Severe Combined Immunodeficiency (SCID-X1)
Eligibility:
- Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
- Newborn to 2 years of age
- No prior therapy with allogeneic stem cell transplantation
- No HIV infection
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia
Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia
Diseases Treated:
Eligibility:
Donor eligibility includes:
- At least 18 years old
- At least single haplotype matched family member
- HIV negative
- Not pregnant or breastfeeding
Recipient eligibility includes:
- 21 years old or younger*
- Diagnosed with relapsed and/or refractory CD19-positive leukemia
- Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
- Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
- Detectable medullary leukemia
* Initial 3 participants must be at least 16 years old.
NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Diseases Treated:
Leukemia and other blood diseases
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
- Participant may be of any age and either gender.
- Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
- Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
NMDPD: Protocol for a Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
National Marrow Donor Program: A research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 25 years old or younger
- Diagnosed with severe sickle cell disease
- Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)
SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia
A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Children and young adults up to 21 years old
- Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)
-
Featured Trials
SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma
Diseases Treated:
Eligibility:
At least 2 years old and younger than 25 years old
Diagnosis of progressive or relapsed low-grade glioma
SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children
Diseases Treated:
Eligibility:
- All patients with newly diagnosed medulloblastoma between birth and 3 years old
- A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
- No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery
Eligibility Exclusions:
- Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure
HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors
Diseases Treated:
Eligibility:
- At least 6 years old and younger than 22
- Diagnosis of low-grade glioma
Loc3CAR: CAR T-Cell Therapy for Pediatric CNS Tumors
Diseases Treated:
Eligibility:
- Up to 21 years old
- Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered.
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors
Diseases Treated:
Recurrent, progressive, or refractory high-grade gliomas
Eligibility:
- Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
- Participant is 1 to 18 years of age
- Participant has bi-measurable disease on MRI
- Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks
PBTC48: Study of the Optune Device in Children with Certain High-Grade Glioma and Ependymoma Brain Tumors
Diseases Treated:
High-grade glioma (HGG), ependymoma
Eligibility:
- Between 5 and 21 years old
- Diagnosis of supratentorial high-grade glioma (HGG) or supratentorial ependymoma that is recurrent, progressive or refractory
- Head circumference of at least 44 cm
- Failed standard therapy with no other available treatment options
- Recovered from prior chemotherapy, immunotherapy or radiotherapy
- Willing and able to use the device at least 18 hours a day for at least 23 days and keep head shaved throughout treatment
PBTC49: Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, HGG or DIPG
Diseases Treated:
Diffuse intrinsic pontine glioma (DIPG)
Eligibility:
- Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
- Evidence of genetic activation of the MET pathway (expansion co-hort)
- At least 5 years old and 21 years old or younger
PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma
Diseases Treated:
Eligibility:
- 12 months to 21 years old with diagnosis of:
- Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
- Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
- 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma
Diseases Treated:
Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor
Eligibility:
- Diagnosed with one of the following:
- Recurrent or refractory solid tumor or central nervous system (CNS) tumor
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Newly diagnosed or recurrent high-grade glioma
- Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma
Diseases Treated:
Eligibility:
At least 2 years old and younger than 25 years old
Diagnosis of progressive or relapsed low-grade glioma
SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children
Diseases Treated:
Eligibility:
- All patients with newly diagnosed medulloblastoma between birth and 3 years old
- A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
- No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery
Eligibility Exclusions:
- Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET
Diseases Treated:
Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)
Eligibility:
- Diagnosis of newly medulloblastoma
- At least 3 years old and younger than 22 years old (Strata W, S or N) OR
- At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
- Has not received previous treatment with radiation therapy or chemotherapy
- Must start treatment within 36 days of surgery to remove the tumor
SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors
Diseases Treated:
Brain tumor
Eligibility:
This study is open only to patients at St. Jude Children’s Research Hospital.
- Diagnosis of medulloblastoma or other brain tumor
- Between 8 and 12 years old
- At least 2 years after completion of therapy
- Full-time student
- Speaks English
-
Featured Trial
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)
Diseases Treated:
Acute Myelogenous Leukemia
Eligibility:
- 21 years old or younger
- Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
- Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
Loc3CAR: CAR T-Cell Therapy for Pediatric CNS Tumors
Diseases Treated:
Eligibility:
- Up to 21 years old
- Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia
Diseases Treated:
Eligibility:
Donor eligibility includes:
- At least 18 years old
- At least single haplotype matched family member
- HIV negative
- Not pregnant or breastfeeding
Recipient eligibility includes:
- 21 years old or younger*
- Diagnosed with relapsed and/or refractory CD19-positive leukemia
- Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
- Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
- Detectable medullary leukemia
* Initial 3 participants must be at least 16 years old.
SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Children and young adults up to 21 years old
- Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)
-
G4K: Genomes for Kids
Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial that is open to St. Jude patients.
- Solid tumor or liquid tumor (cancerous or non-cancerous)
GENETX: Assessment for Gene Therapy Decisions
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)
Diseases Treated:
Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic DiseasesEligibility:
- Non-therapeutic clinical trial
- Interviews conducted remotely
- 18-35-year-olds with rare genetic diseases
- Parents or caregivers of patients under 21 with rare genetic diseases
- Health care workers for gene therapy patients
HSESID: Database for HLH Immunodeficiency Disease
A Registry for Hemophagocytic Lymphohistiocytosis (HLH)
Eligibility:
- Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
- Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
- High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
PG4KDS: Clinical Implementation of Pharmacogenetics
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients
PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer
Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection
Diseases Treated:
None
Eligibility:
This is a non-therapeutic clinical trial that is open only to St. Jude patients.
- Younger than 25 years
- Undergoing cancer therapy at St. Jude Children’s Research Hospital
- Considered to be at high risk of infection
SJFAMILY: Study of Cancer in Families
Familial Investigations of Childhood Cancer Predisposition
Diseases Treated:
Non-therapeutic clinical trial
Eligibility:
This is a non-therapeutic clinical trial that is open to children and adults with familial cancer and to their eligible family members.
Note: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical genetic testing, please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for the SJFAMILY study, as outlined below, you may enroll regardless of the results of your clinical genetic testing.
In this research study, the definition of “Familial Cancer” is met if any of the following is present:
- An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
- An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
- An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR
- An individual with a congenital cancer that was diagnosed before 6 months of age; OR
- An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age. Examples of rare pediatric tumors include (but are not limited to): carcinoma or precursor carcinoma lesions of any organ or anatomic site and cutaneous malignant cancers. Additional rare pediatric tumors to be included will be defined as any solid malignancy or borderline tumor characterized by an annual incidence of less than two occurrences per million per year (such as ectomesenchymoma).
Eligible individuals include:
- An individual who meets the definition of “Familial Cancer,” as above
- Blood relatives of the above individual with familial cancer, who are affected or unaffected by cancer
-
-
COVID-19 Pediatric Vaccine Studies
St. Jude is planning to participate in clinical trials to test COVID-19 prevention vaccines in healthy children. Find out more.
-
REDIRECTED - COVID-19 Vaccine Study ENSEMBLE
St. Jude and UTHSC conducted trials in Memphis for a COVID prevention vaccine for adults. Read about the trial and its early results.
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
-
-
HLHRUXO: Ruxolitinib Therapy for HLH
HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
Diseases Treated:
Hemophagocytic Lymphohistiocytosis
Eligibility:
- 6 weeks to 22 years old
- Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
- Relapsed or refractory HLH
HSESID: Database for HLH Immunodeficiency Disease
A Registry for Hemophagocytic Lymphohistiocytosis (HLH)
Eligibility:
- Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
- Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
- High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
Diseases Treated:
Eligibility:
- Diagnosis of Langerhans cell histiocytosis
- Younger than 18 years old
- Meets inclusion criteria for the respective stratum
-
GENEFU: Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products
Long-Term Follow-Up of Patients who have Received Gene Therapy/Gene Marked Products
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant received an integrating retroviral or lentiviral vector based gene transfer or gene marked product at St. Jude Children’s Research Hospital within the past 15 year time period.
HSESID: Database for HLH Immunodeficiency Disease
A Registry for Hemophagocytic Lymphohistiocytosis (HLH)
Eligibility:
- Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
- Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
- High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
LVXSCID-ND: Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants
A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency (SCID-X1) in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Stem Cells
Diseases Treated:
X-linked Severe Combined Immunodeficiency (SCID-X1)
Eligibility:
- Diagnosis of Severe Combined Immunodeficiency, X-linked (SCID-X1)
- Newborn to 2 years of age
- No prior therapy with allogeneic stem cell transplantation
- No HIV infection
-
-
PURPOSE 2: Study of Lenacapavir for HIV Prevention (GS9023)
A study to test lenacapavir, a new drug that may be able to prevent Human Immunodeficiency Virus (HIV) infection before it occurs. Learn more.
-
HPTN 083-01 HIV Prevention Study
HPTN 083-01 is a study to find out if long-acting, injectable cabotegravir (CAB LA) for PrEP (pre-exposure prophylaxis) is safe and acceptable to use in adolescents.
-
COVID-19 Pediatric Vaccine Studies
St. Jude is planning to participate in clinical trials to test COVID-19 prevention vaccines in healthy children. Find out more.
-
REDIRECTED - COVID-19 Vaccine Study ENSEMBLE
St. Jude and UTHSC conducted trials in Memphis for a COVID prevention vaccine for adults. Read about the trial and its early results.
AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- The subject has been enrolled on IMPAACT P1025.
GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen
A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014
Diseases Treated:
Eligibility:
- Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
- Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
- Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
Diseases Treated:
Eligibility:
- At least 4 weeks old but younger than 18 years old
- Confirmed HIV-1 infection
- Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
PREDSEQ: Identifying Infections Early in Children and Adolescents with Cancer
Prediction of Adverse Events in Children and Adolescents with Cancer at High Risk of Infection
Diseases Treated:
None
Eligibility:
This is a non-therapeutic clinical trial that is open only to St. Jude patients.
- Younger than 25 years
- Undergoing cancer therapy at St. Jude Children’s Research Hospital
- Considered to be at high risk of infection
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
-
-
ALTE1631: Web-based Exercise Study for Children and Adolescents with Cancer
Web-based Physical Activity Intervention among Children and Adolescents with Cancer
Diseases Treated:
leukemia, solid tumor, brain tumor, lymphoma, carcinoma
Eligibility:
This is a non-therapeutic clinical trial open to patients receiving treatment at a Children’s Oncology Group (COG)-affiliated institution.
- At least 8 years old and younger than 16 years old
- Diagnosed with childhood cancer, in remission
- Completed therapy within the past 12 months
- Performance status corresponding to ECOG scores of 0, 1, 2
- Fewer than 420 minutes of moderate to vigorous physical activity (MVPA) over the last week
- Able to write and read English, Spanish or French (patient and at least one parent/guardian)
- Not pregnant
AML23: Clinical Trial Studying the Safety of Using Venetoclax and Chemotherapy to Treat Newly Diagnosed Childhood AML
A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia
Diseases Treated:
Eligibility:
- Diagnosed with AML
- Older than 28 days and younger than 22 years
- No prior AML treatment
APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia (AML)
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
Diseases Treated:
Eligibility:
- Diagnosis of relapsed acute myeloid leukemia (AML)
- Ages 29 days old to 21 years old
- Have had AML come back for the first or second time
- May have heart problems that prevent them from taking anthracyclines
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)
CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia
Diseases Treated:
Acute Myelogenous Leukemia
Eligibility:
- 21 years old or younger
- Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
- Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant
A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
- Ages 12–21 years
- Lymphoid or myeloid-based cancer that requires a bone marrow transplant
DSCOG: Learning, Behavior and Social Skills in Survivors of Childhood Leukemia with Down syndrome
Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia with Down syndrome
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is open only to patients who were treated at St. Jude Children’s Research Hospital since 1980 and are currently followed at the hospital.
- St. Jude Children’s Research Hospital patient with acute leukemia (i.e., ALL or AML)
- Trisomy 21 Down syndrome diagnosis
- Completed all cancer therapy at St. Jude since 1980 and at least six months prior to study visit
- English as the primary language
G4K: Genomes for Kids
Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial that is open to St. Jude patients.
- Solid tumor or liquid tumor (cancerous or non-cancerous)
HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer
TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
For transplant recipient:
- 21 years or younger
- Does not have a suitable sibling donor or volunteer unrelated donor
- Has a suitable single haplotype matched family member donor
- Diagnosed with high risk hematologic malignancy
- No prior allogeneic hematopoietic cell transplant
HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies
Diseases Treated:
Eligibility:
- 21 years and younger
- Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
- Has a suitable single haplotype-matched family member donor
- High-risk hematologic malignancy, including certain diagnoses of:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myelogenous leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL
Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Younger than 22 years old
- Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia
Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia
Diseases Treated:
Eligibility:
Donor eligibility includes:
- At least 18 years old
- At least single haplotype matched family member
- HIV negative
- Not pregnant or breastfeeding
Recipient eligibility includes:
- 21 years old or younger*
- Diagnosed with relapsed and/or refractory CD19-positive leukemia
- Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
- Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
- Detectable medullary leukemia
* Initial 3 participants must be at least 16 years old.
NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Diseases Treated:
Leukemia and other blood diseases
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
- Participant may be of any age and either gender.
- Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
- Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy
Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)
Diseases Treated:
ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
SarcomasEligibility:
This is a research study open only to St. Jude patients and their caregivers.
- 8 to 18 years old
- Within 16 weeks of initial cancer diagnosis
- Receiving outpatient chemotherapy treatment for cancer
- Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
- Have Internet access
RAVEN: Clinical Trial to Treat Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
Diseases Treated:
Acute Lymphoblastic Leukemia and Lymphoma
Eligibility:
- Diagnosed with relapsed or refractory acute lymphoblastic leukemia or lymphoma
- Between 4 and 22 years old
- Weigh more than 20 kg (44.09 lbs.)
- Able to swallow pills
- No prior exposure to navitoclax
- Fully recovered from effects of any prior treatment
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML
A Phase 1 Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
Diseases Treated:
Eligibility:
- Diagnosis of one of the following:
- Relapsed or refractory acute myeloid leukemia (AML)
- Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
- 30 years old or younger (24 years or younger at St. Jude)
- Ineligible for other curative therapy
SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia
A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Children and young adults up to 21 years old
- Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)
-
BMTFU: Protocol for Collecting Long-Term Follow-Up Data on Recipients of Hematopoietic Stem Cell Transplant
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
CCSS: Childhood Cancer Survivor Study
Diseases Treated:
Childhood cancer incidence and survival
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Newly diagnosed with cancer between January 1, 1970, and December 31, 1996
- Survival five years from diagnosis
- Age less than 21 years at the time of diagnosis of cancer
- English or Spanish speaking and living in the United States or Canada at the time of diagnosis
SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer
Eligibility:
- Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude.
SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- All patients being followed or treated at St. Jude Children’s Research Hospital for the diagnosis of childhood cancer
- Patient has not been permanently discharged from care and follow-up
-
APNEA: Sleep Apnea in Hodgkin Lymphoma Survivors Treated with Radiation to the Chest
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated with Thoracic Radiation
Diseases Treated:
Eligibility:
Hodgkin lymphoma survivor
- Patient eligible for the St. Jude LIFE study
- Treated with thoracic radiation for Hodgkin lymphoma
- At least 18 years old
- At least 5 years from original diagnosis
- If participating remotely, must have Wi-Fi access
Comparison group
- Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
- At least 18 years old
- Lives in the U.S.
- If participating remotely, must have Wi-Fi access
cHOD17: Risk-Adapted Therapy for Children and Young Adults with Hodgkin Lymphoma
Pediatric Classical Hodgkin Lymphoma Consortium Study
Diseases Treated:
Eligibility:
- Previously untreated CD30+ classical Hodgkin lymphoma
- 21 years or younger at time of diagnosis (low-risk and intermediate-risk patients)
- 25 years or younger (high-risk patients)
CN160: Ruxolitinib Therapy in Children after Bone Marrow Transplant
A Phase II Pediatric Study of a Graft-vs.-host disease (GVHD) prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic hematopoietic cell transplant for hematological malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
- Ages 12–21 years
- Lymphoid or myeloid-based cancer that requires a bone marrow transplant
G4K: Genomes for Kids
Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial that is open to St. Jude patients.
- Solid tumor or liquid tumor (cancerous or non-cancerous)
HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies
Diseases Treated:
Eligibility:
- 21 years and younger
- Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
- Has a suitable single haplotype-matched family member donor
- High-risk hematologic malignancy, including certain diagnoses of:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myelogenous leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
RAVEN: Clinical Trial to Treat Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
Diseases Treated:
Acute Lymphoblastic Leukemia and Lymphoma
Eligibility:
- Diagnosed with relapsed or refractory acute lymphoblastic leukemia or lymphoma
- Between 4 and 22 years old
- Weigh more than 20 kg (44.09 lbs.)
- Able to swallow pills
- No prior exposure to navitoclax
- Fully recovered from effects of any prior treatment
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
-
DEVOTE: Study of Nusinersen in Children with Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants with Spinal Muscular Atrophy
Diseases Treated:
Eligibility:
- Genetic documentation of 5q spinal muscular atrophy (SMA)
- Ages 1 week to adult (age varies by study part)
DYNEDMD: Study to Measure the Safety and Effectiveness of DYNE-251 in Boys with Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Diseases Treated:
Eligibility:
- Male age 4 to 16 years old
- Diagnosed with Duchenne muscular dystrophy
FACOMS: Friedreich’s Ataxia Clinical Outcome Measures Study
Friedreich’s Ataxia Clinical Outcome Measures Study
Diseases Treated:
Eligibility:
- Patients with Friedreich’s Ataxia
- Birth to 22 years
GENETX: Assessment for Gene Therapy Decisions
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-Aids for Gene Therapy for Rare Diseases (GENETX)
Diseases Treated:
Neurological Disorders
Sickle Cell Disease
Hemophilia
Inherited Genetic DiseasesEligibility:
- Non-therapeutic clinical trial
- Interviews conducted remotely
- 18-35-year-olds with rare genetic diseases
- Parents or caregivers of patients under 21 with rare genetic diseases
- Health care workers for gene therapy patients
INC: Pediatric Study of Charcot-Marie-Tooth Disease
Inherited Neuropathies Consortium Rare Disease Clinical Research Network
Diseases Treated:
Eligibility:
- Patients with Charcot-Marie-Tooth disease
- Birth to 22 years
SAPPHIRE: Efficacy and Safety of Apitegromab in Patients with Spinal Muscular Atrophy Receiving Nusinersen or Risdiplam Therapy
Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy
Diseases Treated:
Spinal Muscular Atrophy Types 2 and 3
Eligibility:
- Between 2 and 21 years old
- Diagnosed with SMA type 2 or type 3 and not able to walk
- Those taking Spinraza must have taken it for at least 10 months.
- Those taking Evrsysdi must have taken it for at least 6 months.
Eligibility exclusions:
- Those who have previously received Zolgensma gene therapy
-
APNEA: Sleep Apnea in Hodgkin Lymphoma Survivors Treated with Radiation to the Chest
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated with Thoracic Radiation
Diseases Treated:
Eligibility:
Hodgkin lymphoma survivor
- Patient eligible for the St. Jude LIFE study
- Treated with thoracic radiation for Hodgkin lymphoma
- At least 18 years old
- At least 5 years from original diagnosis
- If participating remotely, must have Wi-Fi access
Comparison group
- Non-patient volunteer (Cannot be sibling, parent or child of the survivor participant)
- At least 18 years old
- Lives in the U.S.
- If participating remotely, must have Wi-Fi access
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
-
ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors
A Phase I Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Diseases Treated:
Eligibility:
- Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
- Fully recovered from the acute toxic effects of all prior anticancer therapy
- At least 1 but not more than 21 years of age
- Able to swallow tablets whole
FIX-GT: Factor IX Gene Therapy Study for Patients with Hemophilia B
A Factor IX Gene Therapy Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients with Hemophilia B
View TrialFLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Diseases Treated:
Neuroblastoma, pheochromocytoma
Eligibility:
This study is open to St. Jude patients only.
- Known or suspected neuroblastoma or pheochromocytoma
- At least 1 year old
HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors
Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Diseases Treated:
Eligibility:
- At least 6 years old and younger than 22
- Diagnosis of low-grade glioma
HAPSAA: Partially Matched Related Donor Bone Marrow Transplant for Patients with Aplastic Anemia
Haploidentical Donor Hematopoietic Cell Transplantation for Patients with Severe Aplastic Anemia
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosis of severe aplastic anemia
- No available matched donor
HLHRUXO: Ruxolitinib Therapy for HLH
HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
Diseases Treated:
Hemophagocytic Lymphohistiocytosis
Eligibility:
- 6 weeks to 22 years old
- Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
- Relapsed or refractory HLH
INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL
Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Younger than 22 years old
- Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered.
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia
Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia
Diseases Treated:
Eligibility:
Donor eligibility includes:
- At least 18 years old
- At least single haplotype matched family member
- HIV negative
- Not pregnant or breastfeeding
Recipient eligibility includes:
- 21 years old or younger*
- Diagnosed with relapsed and/or refractory CD19-positive leukemia
- Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
- Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
- Detectable medullary leukemia
* Initial 3 participants must be at least 16 years old.
ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Diseases Treated:
Eligibility:
- Ages 12 months old to 30 years
- Diagnosed with recurrent or refractory solid tumor (Phase 1)
- Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
Diseases Treated:
Eligibility:
- At least 4 weeks old but younger than 18 years old
- Confirmed HIV-1 infection
- Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
PBTC49: Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, HGG or DIPG
Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma
Diseases Treated:
Diffuse intrinsic pontine glioma (DIPG)
Eligibility:
- Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
- Evidence of genetic activation of the MET pathway (expansion co-hort)
- At least 5 years old and 21 years old or younger
PEPN1812 : Study of Flotetuzumab in Children with Relapsed or Refractory Acute Myeloid Leukemia
Phase I Trial of Flotetuzumab, a CD123 X CD3 Dual Affinity Re-Targeting (DART) Molecule, in Pediatric Patients with Relapsed/Refractory AML
Diseases Treated:
Eligibility:
- Younger than 21 years of age
- Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
- Weigh more than 17kg
- Fully recovered from the acute toxic effects of all prior anti-cancer therapy
PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Diseases Treated:
Eligibility:
- 12 months to 21 years old with diagnosis of:
- Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
- Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
- 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease
Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.
- Between 6 and 25 years old
- Diagnosed with sickle cell disease
- Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
- Speaks English
PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma
Study of REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Study of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma or Recurrent High-Grade Glioma
Diseases Treated:
Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor
Eligibility:
- Diagnosed with one of the following:
- Recurrent or refractory solid tumor or central nervous system (CNS) tumor
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Newly diagnosed or recurrent high-grade glioma
- Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
SELCLAX: A Study of Venetoclax and Selinexor with Chemotherapy in Children with AML
A Phase 1 Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
Diseases Treated:
Eligibility:
- Diagnosis of one of the following:
- Relapsed or refractory acute myeloid leukemia (AML)
- Relapsed or refractory acute leukemia of ambiguous lineage (ALAL)
- 30 years old or younger (24 years or younger at St. Jude)
- Ineligible for other curative therapy
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma
Phase 1/2 Evaluation of Mirdametinib, a Brain-Penetrant MEK 1/2 Inhibitor, for Children, Adolescents and Young Adults with Low-Grade Glioma
Diseases Treated:
Eligibility:
At least 2 years old and younger than 25 years old
Diagnosis of progressive or relapsed low-grade glioma
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET
Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma
Diseases Treated:
Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)
Eligibility:
- Diagnosis of newly medulloblastoma
- At least 3 years old and younger than 22 years old (Strata W, S or N) OR
- At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
- Has not received previous treatment with radiation therapy or chemotherapy
- Must start treatment within 36 days of surgery to remove the tumor
-
CONNECT: Social Experiences of Adolescents and Young Adults with Cancer
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic research study open only to St. Jude patients and their caregivers.
- 15 to 22 years old
- Primary oncology diagnosis
- Read and speak English
HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors
Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic research study open only to St. Jude patients and their caregivers.
- 5 to 17 years old
- Diagnosed with malignancy or CNS neoplasm
- Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
HEMOCOG: Neurocognitive Functions, Health Literacy, and Transition Readiness in Pediatric Hemophiliacs
Examining Cognition, Health Literacy, Transition Readiness, and Educational Experiences in Patients with Hemophilia
View TrialLEAPS: Understanding Sickle Cell Disease Transition to Adult Care
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition
Diseases Treated:
Eligibility:
This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.
- Diagnosis of sickle cell disease (SCD)
- 16 to 20 years old
- English is primary language
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy
Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)
Diseases Treated:
ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
SarcomasEligibility:
This is a research study open only to St. Jude patients and their caregivers.
- 8 to 18 years old
- Within 16 weeks of initial cancer diagnosis
- Receiving outpatient chemotherapy treatment for cancer
- Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
- Have Internet access
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
SCDCogO2: Analyzing Oxygen Saturation and Neurocognitive Functioning in Patients with Sickle Cell Disease
Cerebral Hemodynamics and Neurocognitive Functioning in Sickle Cell Disease
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
St. Jude Patients
- 8 to 17 years old
- Sickle cell anemia
- Enrolled on the Sickle Cell Clinical Research Intervention Program (SCCRIP) clinical trial
- Completed Sickle Cell Assessment of Neuropsychology Skills (SCANS) assessment
- Being treated with hydroxyurea (maximum tolerated dose)
- Read and speak English
Siblings
- Siblings of St. Jude patients with sickle cell disease
- Do not have sickle cell disease
- 8 to 17 years old
SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 25 years old or younger
- Diagnosed with severe sickle cell disease
- Has a suitable HLA-matched sibling donor or single haplotype matched (half matched) family member donor (parents or siblings)
SEDYC: Social and Emotional Development in Children with Cancer
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic research study open only to St. Jude patients, their parents and patients' teachers.
- Patient between 4 and 6 years old
- Primary diagnosis of brain tumor or non-CNS solid tumor
- 6 to 12 months since therapy was completed (+/- 1 month) OR more than 18 months since therapy completion
- Chemotherapy was part of tumor treatment
- Able to speak and read English
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET
Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma
Diseases Treated:
Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)
Eligibility:
- Diagnosis of newly medulloblastoma
- At least 3 years old and younger than 22 years old (Strata W, S or N) OR
- At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
- Has not received previous treatment with radiation therapy or chemotherapy
- Must start treatment within 36 days of surgery to remove the tumor
SOCFUN: Social Functioning in Survivors of Pediatric Brain Tumors
Components of Social Functioning in Survivors of Pediatric Brain Tumors
Diseases Treated:
Brain tumor
Eligibility:
This study is open only to patients at St. Jude Children’s Research Hospital.
- Diagnosis of medulloblastoma or other brain tumor
- Between 8 and 12 years old
- At least 2 years after completion of therapy
- Full-time student
- Speaks English
-
EPCP1: Exploring the Role of Palliative Care in Childhood Cancer Patients
Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic research study open only to St. Jude patients and their caregivers.
- Caregiver is 18 years of age or older
- Caregiver is the patient’s biological parent, stepparent or primary legal guardian
- If more than 1 set of parents are involved in the patient’s care (e.g., 2 biologic and 2 stepparents or partners), the caregiver with legal decision-making responsibilities will be eligible for participation
- Caregiver is comfortable speaking and reading English
HBTOP: Healthy Lifestyle Behaviors of Childhood Cancer Survivors
Patterns and Correlates of Healthy Lifestyle Behaviors Among Children and Adolescents Transitioning Off Active Therapy
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic research study open only to St. Jude patients and their caregivers.
- 5 to 17 years old
- Diagnosed with malignancy or CNS neoplasm
- Identified by the St. Jude Transition Oncology Program as a patient transitioning off active cancer therapy
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy
Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)
Diseases Treated:
ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
SarcomasEligibility:
This is a research study open only to St. Jude patients and their caregivers.
- 8 to 18 years old
- Within 16 weeks of initial cancer diagnosis
- Receiving outpatient chemotherapy treatment for cancer
- Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
- Have Internet access
U-CHAT: Understanding Communication in Health Care to Achieve Trust
Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression
Diseases Treated:
Non-therapeutic
Eligibility:
Primary oncologist:
- Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
- Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)
Parents of children with cancer:
- Age 18 or older
- Biological parent, step-parent or primary legal guardian
- Reads and speaks English
Patients:
- Primary oncologist is enrolled in the study.
- 30 years old or younger
- Diagnosed with a solid tumor and/or a brain tumor
-
DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment.
- Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI.
- Participant meets institutional MRI safety screening requirements.
- Participant has not undergone primary tumor resection prior to arrival to St. Jude.
HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors
Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Diseases Treated:
Eligibility:
- At least 6 years old and younger than 22
- Diagnosis of low-grade glioma
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
SJPROTON2: Effects of Patient Positioning on Accuracy of Pediatric Proton Therapy
Estimating Setup Uncertainty in Pediatric Proton Therapy Using Volumetric Images
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial open only to St. Jude patients.
- St. Jude patients receiving at least 5 daily fractions of proton therapy
- All patients receiving proton therapy at St. Jude will be screened for participation.
SJWT21: Study of Proton Therapy in Patients with Wilms Tumor following Nephrectomy
Multi-Center Trial for the Treatment of Patients with Stage III-V Wilms Tumor Requiring Abdominal Radiation Delivered with Proton Beam Irradiation following Nephrectomy or Partial Nephrectomy
View Trial -
BHEEM: Study of BEAM-101 in Patients with Severe Sickle Cell Disease
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 18 to 35 years old
- Diagnosed with severe sickle cell disease
BMR: Bone Marrow Collection for Sickle Cell and Thalassemia Research
Bone Marrow for Hemoglobinopathy Research
Diseases Treated:
Sickle cell anemia, thalassemia
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- At least 2 years old
- Diagnosed with sickle cell anemia or thalassemia
- No active disease, including painful crisis or active infection
- Adequate blood counts
CASPERKID: Study of Exa-cel in Children with Severe Sickle Cell Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (Exagamglogene Autotemcel or Exa-cel) in Subjects with Severe Sickle Cell Disease
Diseases Treated:
Eligibility:
- 2–11 years old
- Diagnosed with severe sickle cell disease (SCD)
INSIGHT-HD: Investigating the Genetics of Hematologic Diseases
Diseases Treated:
Non-malignant blood diseases (non-therapeutic)
Eligibility:
- Receiving therapy or a consultation for a non-malignant blood disorder
- Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
LEAPS: Understanding Sickle Cell Disease Transition to Adult Care
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Health Care Transition
Diseases Treated:
Eligibility:
This is a non-therapeutic study for patients at St. Jude Children’s Research Hospital and Methodist Adult Comprehensive Sickle Cell Center.
- Diagnosis of sickle cell disease (SCD)
- 16 to 20 years old
- English is primary language
PMVOCVR: Virtual Reality Therapy for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease
Virtual Reality Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is open only to patients at St. Jude or Methodist Healthcare.
- Between 6 and 25 years old
- Diagnosed with sickle cell disease
- Seeking care for acute vaso-occlusive crisis pain at St. Jude Children’s Research Hospital or Methodist Healthcare
- Speaks English
SCCRIP: Sickle Cell Research and Intervention Program
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.- Participant has a diagnosis of Sickle Cell Disease of any genotype.
-
Featured Trial
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors
B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)
Diseases Treated:
Solid Tumors
Eligibility:
Inclusion criteria include:
- 21 years old or younger
- Relapsed or refractory B7-H3-positive solid tumor
ADV1414: Phase I Study of Selinexor to Treat Patients with Recurrent and Refractory Pediatric Solid Tumors
A Phase I Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Diseases Treated:
Eligibility:
- Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
- Fully recovered from the acute toxic effects of all prior anticancer therapy
- At least 1 but not more than 21 years of age
- Able to swallow tablets whole
ANBL1821: Study of Eflornithine with Chemo-Immunotherapy for Children with Advanced Neuroblastoma
Phase II Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Diseases Treated:
Eligibility:
- At least 1 year old
- Diagnosis of relapsed, refractory or progressive neuroblastoma
ANGIO-A: Study of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children and Young Adults with Solid Tumors
Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients
Diseases Treated:
Solid tumors
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Sarcomas
Malignant rhabdoid tumors
Desmoplastic small round cell tumorsEligibility:
Part 1
- 1–30 years old
- Diagnosis of a solid tumor that has grown or has come back after treatment
- Tumor accessible through biopsy
Part 2
- 1–30 years old
- Diagnosis of:
- Hepatocellular carcinoma that has grown or has come back after treatment
- Fibrolamellar hepatocellular carcinoma
- Desmoplastic small round cell tumor
- Malignant rhabdoid tumor that is not in the central nervous system
- Tumor accessible through biopsy
AOST2032: Cabozantinib with Chemotherapy for Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Diseases Treated:
Eligibility:
- Less than 40 years old
- A new diagnosis of high-grade osteosarcoma
- Must be able to swallow tablets
- The current phase is only open to patients with metastatic disease
DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas
Diseases Treated:
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment.
- Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI.
- Participant meets institutional MRI safety screening requirements.
- Participant has not undergone primary tumor resection prior to arrival to St. Jude.
FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Diseases Treated:
Neuroblastoma, pheochromocytoma
Eligibility:
This study is open to St. Jude patients only.
- Known or suspected neuroblastoma or pheochromocytoma
- At least 1 year old
G4K: Genomes for Kids
Next Generation Sequencing of Normal Tissue Prospectively in Pediatric Oncology Patients
Diseases Treated:
Non-therapeutic
Eligibility:
This is a non-therapeutic clinical trial that is open to St. Jude patients.
- Solid tumor or liquid tumor (cancerous or non-cancerous)
IPACTR: International Pediatric Adrenocortical Tumor Registry
Diseases Treated:
Adrenocortical tumors (carcinoma and adenoma)
Eligibility:
- Diagnosis of an adrenocortical tumor (ACT)
- 21 years of age or younger at diagnosis
- Relatives of patients with ACT
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MACMEL: A Study to Analyze Melanoma Lesions in Children and Teens
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Diseases Treated:
Eligibility:
- Diagnosed with a melanoma tumor that is malignant (cancerous) or that might be cancerous, including:
- Conventional or “adult-type” melanoma
- Spitzoid melanoma/atypical Spitz tumor
- Congenital melanoma
- Melanoma arising in a giant congenital nevus
- Melanocytic lesions with indeterminate biological behavior (e.g., pigment-synthesizing melanomas)
- Younger than 19 years of age
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered.
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (ANBL1232)
Diseases Treated:
Neuroblastoma, ganglioneuroblastoma
Eligibility:
- Participant has been enrolled on ANBLB1 (ANBL00B1).
- Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
- Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.
ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma
Diseases Treated:
Eligibility:
- Ages 12 months old to 30 years
- Diagnosed with recurrent or refractory solid tumor (Phase 1)
- Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
PAINBDY1: Treating Pain in Children with Cancer: Pain Buddy
Treating Pain in Children with Cancer: A 21st Century Innovative Approach (Pain Buddy)
Diseases Treated:
ALL
AML
Carcinoma
Endocrine Tumors
Lymphoma
Melanoma
Neuroblastoma
Retinoblastoma
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
SarcomasEligibility:
This is a research study open only to St. Jude patients and their caregivers.
- 8 to 18 years old
- Within 16 weeks of initial cancer diagnosis
- Receiving outpatient chemotherapy treatment for cancer
- Can speak, read and write English. Parents who can speak, read, and write in English and Spanish
- Have Internet access
PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; anti PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG), DIPGs and Hypermutated Brain Tumors
Diseases Treated:
Recurrent, progressive, or refractory high-grade gliomas
Eligibility:
- Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
- Participant is 1 to 18 years of age
- Participant has bi-measurable disease on MRI
- Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks
PEPN2111: Study of CBL0137 in Patients with Relapsed or Refractory Solid Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Diseases Treated:
Eligibility:
- 12 months to 21 years old with diagnosis of:
- Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
- Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
- 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma
PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma
Study of REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Study of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma or Recurrent High-Grade Glioma
Diseases Treated:
Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor
Eligibility:
- Diagnosed with one of the following:
- Recurrent or refractory solid tumor or central nervous system (CNS) tumor
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Newly diagnosed or recurrent high-grade glioma
- Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)
RBAPP: Smartphone App for Retinoblastoma
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Diseases Treated:
Eligibility:
This study is currently open only to patients at St. Jude Children's Research Hospital.
- 7 years old or younger
- Part I
- Diagnosed with retinoblastoma and has not received any treatment OR
- Diagnosed with cataracts and has not received any treatment OR
- Diagnosed with glaucoma and has not received any treatment
- Part II
- Referred to an eye doctor to check for leukocoria or other eye conditions
- Part III
- Diagnosed with retinoblastoma and is receiving treatment
SJWT21: Study of Proton Therapy in Patients with Wilms Tumor following Nephrectomy
Multi-Center Trial for the Treatment of Patients with Stage III-V Wilms Tumor Requiring Abdominal Radiation Delivered with Proton Beam Irradiation following Nephrectomy or Partial Nephrectomy
View TrialU-CHAT: Understanding Communication in Health Care to Achieve Trust
Understanding Communication in Health Care to Achieve Trust: A Prospective Longitudinal Investigation of Communication between Pediatric Oncologists, Children/Adolescents with High-Risk Cancer, and their Families at the Stressful Times of Disease Relapse or Progression
Diseases Treated:
Non-therapeutic
Eligibility:
Primary oncologist:
- Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor or Neuro-Oncology Clinics at St. Jude Children’s Research Hospital
- Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)
Parents of children with cancer:
- Age 18 or older
- Biological parent, step-parent or primary legal guardian
- Reads and speaks English
Patients:
- Primary oncologist is enrolled in the study.
- 30 years old or younger
- Diagnosed with a solid tumor and/or a brain tumor
-
IPACTR: International Pediatric Adrenocortical Tumor Registry
Diseases Treated:
Adrenocortical tumors (carcinoma and adenoma)
Eligibility:
- Diagnosis of an adrenocortical tumor (ACT)
- 21 years of age or younger at diagnosis
- Relatives of patients with ACT
TBANK: Protocol for Collecting, Banking, and Distributing Human Tissue Samples: St. Jude Children’s Research Hospital Biorepository
Eligibility:
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
-
SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity
Eligibility:
- Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
- Child has adequate blood, liver and kidney function.
- Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.